Lulizumab pegol is under investigation in clinical trial NCT02843659,Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sj鰃ren's Syndrome.

货号（Catalog No.）

CSD00351

通用名INN

Lulizumab Pegol

纯度(Purity)

>95%

浓度( Concentration)

1mg/ml

Formulation

PBS buffer pH7.5

Source

CHO cells

内毒素(Endotoxin level)

Please contact with the lab for this information.

生物活性

产品描述(Description)

Lulizumab pegol is under investigation in clinical trial NCT02843659,Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sj?gren's Syndrome.

别名(Alternative names)

BMS-931699

靶点;物种(Specificity target name;species)

CD28 [Homo sapiens]

种类(Species)

Humanized

受体鉴定(Receptor identification)

V-kappa

化学信息

CAS

1421830-13-8

存储条件(Storage)

store at -80°C